The Role of HS-1200 Induced Autophagy in Oral Cancer Cells.
- Author:
Nam Mi JANG
1
;
Sang Hun OH
;
In Ryoung KIM
;
Hae Ryoun PARK
;
Bong Soo PARK
Author Information
1. Department of Oral Anatomy, School of Dentistry, Pusan National University, Yangsan, Korea. parkbs@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
HS-1200;
autophagy;
apoptosis;
OSCC
- MeSH:
Acridine Orange;
Apoptosis;
Autophagy;
Bile;
Bile Acids and Salts;
Biomarkers;
Cadaverine;
Carcinoma, Squamous Cell;
Cell Death;
Chenodeoxycholic Acid;
Mouth Neoplasms;
Vacuoles
- From:International Journal of Oral Biology
2013;38(3):93-100
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bile acids and synthetic bile acid derivatives induce apoptosis in various kinds of cancer cells and thus have anticancer properties. Recently, it has been suggested that autophagy may play an important role in cancer therapy. However, few data are available regarding the role of autophagy in oral cancers and there have been no reports of autophagic cell death in OSCCs (oral squamous cell carcinoma cells) induced by HS-1200, a synthetic bile acid derivative. We thus examine whether HS-1200 modulates autophagy in OSCCs. Our findings indicate that HS-1200 has anticancer effects in OSCCs, and we observed in these cells that autophagic vacuoles were visible by monodansylcadaverine (MDC)and acridine orange staining. When we analyzed HS-1200-treated OSCC cells for the presence of biochemical markers, we observed that this treatment directly affects the conversion of LC-3II, degradation of p62/SQSTM1 and full-length beclin-1, cleavage of ATG5-12 and the activation of caspase. An autophagy inhibitor suppressed HS-1200-induced cell death in OSCCs, confirming that autophagy acts as a pro-death signal in these cells. Furthermore, HS-1200 shows anticancer activity against OSCCs via both autophagy and apoptosis. Our current findings suggest that HS-1200 may potentially contribute to oral cancer treatment and thus provide useful information for the future development of a new therapeutic agent.
